Our finding of an increase in cutaneous vasculitis and polyarteritis after COVID-19 infection is not unexpected given that cutaneous small-vessel vasculitis or capillaritis such as leukocytoclastic vasculitis is frequently associated with perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) and antibodies against myeloperoxidase (anti-MPO) and is seen after a variety of infections (streptococcal and hepatitis infection in Henoch–Schonlein purpura) and environmental insults (levamisole in therapeutic and illicit drugs) (7, 8). This evidence concerns the gene MPO and polyarteritis nodosa.